Zimislecel: Type 1 Diabetes Cell Therapy Restores Islet Function
- A novel stem cell-derived therapy, zimislecel, is demonstrating encouraging results for individuals with type 1 diabetes, according to a recent study.
- In a trial involving 12 participants, all demonstrated engraftment and islet function, with glucose-responsive endogenous C-peptide production, throughout a year of follow-up.
- Additionally,all participants remained free from severe hypoglycemic events from day 90 through the one-year mark.
Promising results from a stem cell therapy, zimislecel, offer a beacon of hope for those with type 1 diabetes. A recent study demonstrated that all participants showed restored islet function, possibly paving the way for insulin independence and improved glucose control. Findings reveal meaningful reductions in exogenous insulin use, with the majority no longer requiring it after a year. News Directory 3 reports on this groundbreaking research, presented at the American Diabetes Association Scientific Sessions, emphasizing the potential of zimislecel to transform diabetes care. This ”stem cell therapy” showed the the elimination of severe hypoglycemic events. The research shows that is safe. Further studies are planned. Discover what’s next for this innovative treatment.
stem Cell Therapy Shows Promise for Type 1 Diabetes
Updated June 22, 2025
A novel stem cell-derived therapy, zimislecel, is demonstrating encouraging results for individuals with type 1 diabetes, according to a recent study. The treatment aims to restore the physiologic function of islets, potentially leading to improved glycemic control and insulin independence.
In a trial involving 12 participants, all demonstrated engraftment and islet function, with glucose-responsive endogenous C-peptide production, throughout a year of follow-up. The study also found that all participants achieved a target HbA1c less than 7% and maintained glucose levels within the target range of 70 mg/dL to 180 mg/dL for more than 70% of the time.
Additionally,all participants remained free from severe hypoglycemic events from day 90 through the one-year mark. The research indicated a meaningful reduction in exogenous insulin use, with a mean reduction in daily dose of 92%. Notably, 10 of the 12 participants (83%) no longer required exogenous insulin after one year.
The study met its primary endpoint, which was the elimination of severe hypoglycemic events alongside an HbA1c level below 7%.The findings were presented at the American Diabetes Association Scientific Sessions.
Michael R. Rickels
zimislecel was generally well-tolerated, with no serious adverse events related to the treatment reported during the follow-up period.common adverse events included diarrhea, headache, and nausea, according to Michael R. Rickels. Researchers also observed neutropenia,transient elevations in liver aminotransferase levels,and decreased renal function. Two patients died from causes unrelated to the zimislecel treatment. According to Vertex, the safety profile aligns with immunosuppression, the infusion procedure, and complications arising from long-standing diabetes.
Marlon Pragnell,vice president of research and science at the ADA,said stem cell therapy is showing tremendous promise in transforming type 1 diabetes care,offering real hope for insulin independence.
“Directed differentiation of pluripotent stem cells into specialized cell types can potentially provide an inexhaustible supply of replacement tissues for serious diseases. Our study showed that stem cell-derived islets engrafted, produced exogenous insulin and restored the physiologic function of islets, leading to improved glycemic control, elimination of severe hypoglycemic events and insulin independence in persons with type 1 diabetes,” the researchers wrote.
What’s next
The researchers support further studies of zimislecel in larger, longer trials involving diverse populations.The FORWARD-101 study,an ongoing open-label 5-year study,is underway. A phase 3 study is expected to complete enrollment of approximately 50 individuals by the end of the summer, according to Rickels.